The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer

키워드

참고문헌 (33)

1. Byung-Woo Kim, "Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database", Gut and Liver, 13(1), pp.104~113 (2019), 거트앤리버 소화기연관학회협의회[DOI]
2. Azoury SC, "Immune checkpoint inhibitors for cancer therapy : clinical efficacy and safety", Curr Cancer Drug Targets, 15, pp.452~462 (2015)
3. LaFleur MW, "Inhibitors of the PD-1 pathway in tumor therapy", J Immunol, 200, pp.375~383 (2018)
4. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
5. Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
6. Bang YJ, "Pembrolizumab(pembro)for advanced biliary adenocarcinoma : results from the KEYNOTE-028(KN028)and KEYNOTE-158(KN158)basket studies", J Clin Oncol, 37(15_suppl), pp.4079~ (2019)
7. Xie Q, "Prognostic and clinicopathological significance of PD-L1 in patients with cholangiocarcinoma : a meta-analysis", Dis Markers, 2020, pp.1817931~ (2020)
8. Xu G, "The clinicopathological and prognostic value of PD-L1 expression in cholangiocarcinoma : a meta-analysis", Front Oncol, 9, pp.897~ (2019)
9. Kriegsmann M, "Programmed cell death ligand 1(PD-L1, CD274)in cholangiocarcinoma : correlation with clinicopathological data and comparison of antibodies", BMC Cancer, 19, pp.72~ (2019)
10. Dong Z, "Expression of programmed death ligand 1 is associated with the prognosis of intrahepatic cholangiocarcinoma", Dig Dis Sci, 65, pp.480~488 (2020)
11. Sangkhamanon S, "Programmed death-ligand 1(PD-L1)expression associated with a high neutrophil", lymphocyte ratio in cholangiocarcinoma, 2017, pp.18, 1671~1674
12. Zhou Dexi, "Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?", Gut and Liver, 15(4), pp.500~516 (2021), 거트앤리버 소화기연관학회협의회[DOI]
13. Goeppert B, "Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer", Br J Cancer, 109, pp.2665~2674 (2013)
14. Nimmagadda S, "Quantifying PD-L1 expression to monitor immune checkpoint therapy: opportunities and challenges", Cancers(Basel), 12, pp.3173~ (2020)
15. Contal C, "An application of changepoint methods in studying the effect of age on survival in breast cancer", Comput Stat Data Anal, 30, pp.253~270 (1999)
16. Dong H, "Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion", Nat Med, 8, pp.793~800 (2002)
17. Boussiotis VA, "Molecular and biochemical aspects of the PD-1 checkpoint pathway", N Engl J Med, 375, pp.1767~1778 (2016)
18. Kim HR, "PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients", Sci Rep, 6, pp.36956~ (2016)
19. Sznurkowski JJ, "PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients", Oncotarget, 8, pp.89903~89912 (2017)
20. Kim DH, "Clinical significance of tumor and immune cell PD-L1 expression in gastric adenocarcinoma", In Vivo, 34, pp.3171~3180 (2020)
21. Junttila A, "Immune cell score, PD-L1 expression and prognosis in esophageal cancer", Acta Oncol, 60, pp.544~548 (2021)
22. Jiang X, "Role of the tumor microenvironment in PD-L1", PD-1-mediated tumor immune escape, 2019, pp.18, 10~
23. Ahn S, "High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer", Sci Rep, 10, pp.12348~ (2020)
24. Valero C, "Response rates to anti-PD-1immunotherapy in microsatellite-stable solid tumors with 10or more mutations per megabase", JAMA Oncol, 7, pp.739~743 (2021)
25. Evrard C, "Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer", Cancers(Basel), 11, pp.1567~ (2019)
26. Marabelle A, "Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability", mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 study, 2020, pp.38, 1~10
27. Kim ST, "Correlating programmed death ligand 1(PD-L1)expression, mismatch repair deficiency, and outcomes across tumor types : implications for immunotherapy", Oncotarget, 8, pp.77415~77423 (2017)
28. Jakubowski CD, "Immune checkpoint inhibitor therapy in biliary tract cancer(cholangiocarcinoma)", Chin Clin Oncol, 9, pp.2~ (2020)
29. Benson AB, "Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 19, pp.541~565 (2021)
30. 강준호, "Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response", Cancer Research and Treatment, 52(2), pp.594~603 (2020), 대한암학회
31. Sakakibara R, "EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer", Clin Lung Cancer, 18, pp.527~534 (2017)
32. Kim HS, "Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer", Gynecol Oncol, 151, pp.414~421 (2018)
33. Sul J, "FDA approval summary : pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1", Oncologist, 21, pp.643~650 (2016)

관련 논문AI추천